BVF Inc. IL Takes Position in NewAmsterdam Pharma Company N.V. $NAMS

Key Points

• BVF Inc. IL invested approximately $1.21 million in NewAmsterdam Pharma during the first quarter, acquiring 59,065 shares of stock.
• NewAmsterdam Pharma reported an earnings per share (EPS) of ($0.15) for the last quarter, exceeding analysts' expectations by $0.37.
• Institutional investors own 89.89% of NewAmsterdam Pharma's stock, with various funds recently increasing their positions in the company.

BVF Inc. IL acquired a new position in NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Free Report) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 59,065 shares of the company's stock, valued at approximately $1,209,000. BVF Inc. IL owned 0.05% of NewAmsterdam Pharma as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also made changes to their positions in the company. Barclays PLC increased its position in shares of NewAmsterdam Pharma by 120.0% during the fourth quarter. Barclays PLC now owns 16,713 shares of the company's stock valued at $429,000 after purchasing an additional 9,117 shares during the period. Tudor Investment Corp ET AL acquired a new position in NewAmsterdam Pharma during the 4th quarter worth $1,342,000. The Manufacturers Life Insurance Company bought a new stake in shares of NewAmsterdam Pharma during the 4th quarter valued at $221,000. Northern Trust Corp bought a new stake in shares of NewAmsterdam Pharma during the 4th quarter valued at $556,000. Finally, Schonfeld Strategic Advisors LLC bought a new stake in shares of NewAmsterdam Pharma during the 4th quarter valued at $524,000. 89.89% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms recently commented on NAMS. Royal Bank Of Canada upped their price objective on shares of NewAmsterdam Pharma from $38.00 to $39.00 and gave the company an "outperform" rating in a research report on Thursday, August 7th. Citigroup assumed coverage on NewAmsterdam Pharma in a report on Tuesday, June 17th. They set a "buy" rating and a $42.00 target price for the company. Cantor Fitzgerald assumed coverage on NewAmsterdam Pharma in a report on Wednesday, June 4th. They issued an "overweight" rating and a $42.00 price target on the stock. Wells Fargo & Company assumed coverage on NewAmsterdam Pharma in a report on Monday, August 25th. They issued an "overweight" rating and a $45.00 price target on the stock. Finally, Wall Street Zen upgraded NewAmsterdam Pharma from a "sell" rating to a "hold" rating in a report on Saturday, July 5th. Nine research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $41.55.

NewAmsterdam Pharma Stock Up 5.2%

Shares of NASDAQ:NAMS traded up $1.34 during midday trading on Friday, reaching $27.00. The company had a trading volume of 1,570,503 shares, compared to its average volume of 806,032. The business's 50 day moving average price is $22.98 and its 200 day moving average price is $20.56. The stock has a market cap of $3.04 billion, a PE ratio of -16.67 and a beta of -0.01. NewAmsterdam Pharma Company N.V. has a 1-year low of $14.06 and a 1-year high of $27.29.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last released its earnings results on Wednesday, August 6th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.52) by $0.37. The business had revenue of $19.15 million for the quarter, compared to the consensus estimate of $1.44 million. NewAmsterdam Pharma had a negative return on equity of 27.27% and a negative net margin of 259.07%. On average, research analysts expect that NewAmsterdam Pharma Company N.V. will post -1.75 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director James N. Topper bought 2,520 shares of the stock in a transaction that occurred on Tuesday, June 24th. The shares were acquired at an average price of $18.43 per share, with a total value of $46,443.60. Following the completion of the transaction, the director owned 3,024,873 shares in the company, valued at $55,748,409.39. The trade was a 0.08% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Johannes Jacob Piete Kastelein sold 50,000 shares of NewAmsterdam Pharma stock in a transaction dated Thursday, August 21st. The shares were sold at an average price of $24.29, for a total value of $1,214,500.00. Following the completion of the sale, the insider directly owned 119,302 shares in the company, valued at approximately $2,897,845.58. This represents a 29.53% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders acquired 12,835 shares of company stock worth $248,134 and sold 274,954 shares worth $5,899,406. 20.84% of the stock is owned by insiders.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.